Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders
Christian Hölscher
British Journal of Pharmacology (2021) Vol. 179, Iss. 4, pp. 695-714
Open Access | Times Cited: 94

Showing 1-25 of 94 citing articles:

Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
Agata Winiarska, Monika Knysak, Katarzyna Nabrdalik, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 19, pp. 10822-10822
Open Access | Times Cited: 123
The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review
Niklas Reich, Christian Hölscher
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 106
Type 2 diabetes mellitus-associated cognitive dysfunction: Advances in potential mechanisms and therapies
Ailin Luo, Zheng Xie, Yue Wang, et al.
Neuroscience & Biobehavioral Reviews (2022) Vol. 137, pp. 104642-104642
Closed Access | Times Cited: 82
Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway
Zhaojun Wang, Xinru Li, Shi-Fan Chai, et al.
Neuropharmacology (2023) Vol. 240, pp. 109716-109716
Closed Access | Times Cited: 42
Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?
Christian Hölscher
Neuropharmacology (2024) Vol. 253, pp. 109952-109952
Open Access | Times Cited: 19
Cell-Penetrating Peptides: Promising Therapeutics and Drug-Delivery Systems for Neurodegenerative Diseases
Mitra Pirhaghi, Fatemeh Mamashli, Faezeh Moosavi-Movahedi, et al.
Molecular Pharmaceutics (2024) Vol. 21, Iss. 5, pp. 2097-2117
Closed Access | Times Cited: 15
Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment
Stefan Trapp, Daniel I. Brierley
British Journal of Pharmacology (2021) Vol. 179, Iss. 4, pp. 557-570
Open Access | Times Cited: 87
Cerebrovascular insulin receptors are defective in Alzheimer’s disease
Manon Leclerc, Philippe Bourassa, Cyntia Tremblay, et al.
Brain (2022) Vol. 146, Iss. 1, pp. 75-90
Open Access | Times Cited: 55
Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?
C. Meurot, C. Jacques, C. Martin, et al.
Journal of Orthopaedic Translation (2022) Vol. 32, pp. 121-129
Open Access | Times Cited: 40
Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset
Stefania Chiappini, Rachel Vickers‐Smith, Daniel R. Harris, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 994-994
Open Access | Times Cited: 34
Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes
Fu‐Shun Yen, Ming‐Chih Hou, James Cheng‐Chung Wei, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 22, Iss. 6, pp. 1255-1264.e18
Closed Access | Times Cited: 23
Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity
Rafael Tamayo‐Trujillo, Viviana A. Ruiz‐Pozo, Santiago Cadena-Ullauri, et al.
Frontiers in Nutrition (2024) Vol. 11
Open Access | Times Cited: 12
Addressing neurodegeneration in glaucoma: Mechanisms, challenges, and treatments
Ghazi O. Bou Ghanem, Lauren K. Wareham, David J. Calkins
Progress in Retinal and Eye Research (2024) Vol. 100, pp. 101261-101261
Open Access | Times Cited: 11
DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson’s disease
Seong‐Jin Yu, Yun Wang, Hui Shen, et al.
GeroScience (2024) Vol. 46, Iss. 5, pp. 4349-4371
Open Access | Times Cited: 10
Liraglutide Reduces Alcohol Consumption, Anxiety, Memory Impairment, and Synapse Loss in Alcohol Dependent Mice
Weizhen Liu, Ziliang Wang, Wang Wang, et al.
Neurochemical Research (2024) Vol. 49, Iss. 4, pp. 1061-1075
Open Access | Times Cited: 9
Targeting organ-specific mitochondrial dysfunction to improve biological aging
Corina T. Madreiter‐Sokolowski, Ursula Hiden, Jelena Krstić, et al.
Pharmacology & Therapeutics (2024) Vol. 262, pp. 108710-108710
Open Access | Times Cited: 8
Neuroprotective Mechanisms of Glucagon-Like Peptide-1-Based Therapies in Ischemic Stroke: An Update Based on Preclinical Research
Xiaoyan Yang, Qiang Qiang, Nan Li, et al.
Frontiers in Neurology (2022) Vol. 13
Open Access | Times Cited: 37
Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Yolanda Diz-Chaves, Zainab Mastoor, Carlos Spuch, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 9583-9583
Open Access | Times Cited: 37
Chlorogenic Acid: a Polyphenol from Coffee Rendered Neuroprotection Against Rotenone-Induced Parkinson’s Disease by GLP-1 Secretion
Nishant Sharma, Ritu Soni, Monika Sharma, et al.
Molecular Neurobiology (2022) Vol. 59, Iss. 11, pp. 6834-6856
Closed Access | Times Cited: 34
Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives
Federica Ferrari, Antonio Moretti, R. F. Villa
Pharmacology & Therapeutics (2022) Vol. 239, pp. 108277-108277
Closed Access | Times Cited: 32
A Systematic Review of Semaglutide’s Influence on Cognitive Function in Preclinical Animal Models and Cell-Line Studies
Raluca Oana Tipa, Daniela-Gabriela Bălan, Mihai Géorgescu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 4972-4972
Open Access | Times Cited: 6
Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson’s disease
Xiaoyan Yang, Peng Feng, Rong Ji, et al.
Expert Opinion on Therapeutic Targets (2022) Vol. 26, Iss. 5, pp. 445-460
Closed Access | Times Cited: 26
Cholecystokinin and glucagon-like peptide-1 analogues regulate intestinal tight junction, inflammation, dopaminergic neurons and α-synuclein accumulation in the colon of two Parkinson's disease mouse models
Yunfang Su, Ningning Liu, Zijuan Zhang, et al.
European Journal of Pharmacology (2022) Vol. 926, pp. 175029-175029
Closed Access | Times Cited: 24
Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer’s and Parkinson’s diseases
Christian Hölscher
Frontiers in Synaptic Neuroscience (2022) Vol. 14
Open Access | Times Cited: 24
Page 1 - Next Page

Scroll to top